NASDAQ$DCGO
Docgo Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
DocGo reported a decrease in total revenue primarily due to the wind-down of migrant-related programs, while full-year GAAP gross margin improved.
DocGo's fourth quarter 2024 revenue decreased to $120.8 million from $199.2 million in the prior year, mainly due to the wind-down of migrant-related programs. The company reported a net loss of $7.6 million for the quarter, compared to a net income of $8.0 million in Q4 2023. Full-year 2024 revenue was $616.6 million, with a GAAP gross margin of 32.1%.
- Total revenue for Q4 2024 was $120.8 million, a significant decrease from $199.2 million in Q4 2023, primarily due to the wind-down of migrant-related programs.
- The company reported a net loss of $7.6 million in Q4 2024, contrasting with a net income of $8.0 million in Q4 2023.
- Adjusted EBITDA for Q4 2024 was $1.1 million, down from $22.6 million in Q4 2023.
- Full-year 2024 revenue was $616.6 million, with full-year GAAP gross margin improving to 32.1% from 28.7% in 2023.
Headline financials
Revenue & EPS history
Docgo · Revenue · Quarterly
$121M
Revenue by segment
Docgo · $187M total across 2 segments · Q3 2023
- Mobile Health Services$139M—74.7%
- Transportation Services$47.2M—25.3%
Forward guidance
DocGo expects full-year 2025 revenue to be between $410 million and $450 million, unchanged from previous estimates. However, the adjusted EBITDA margin for 2025 is now expected to be approximately 5%, down from the previous estimate of 8%-10%.
Tailwinds
- Full-year 2025 revenue guidance remains unchanged at $410-$450 million.
- Continued strong demand for care gap closure programs in payer and provider verticals.
- Expansion of training initiatives and broadening of service scope.
- High Net Promoter Score (NPS) of 86 for care gap closure programs in Q4, indicating strong patient and customer satisfaction.
- Confidence in second-half revenues from government population health pipeline, including subcontracted and direct opportunities.
Headwinds
- Full-year 2025 adjusted EBITDA margin is now expected to be approximately 5%, down from the previous estimate of 8%-10%.
- Increased investment to support the growth of care gap closure programs.
- Costs associated with expanding mobile health offerings.
- Expenses related to transitioning operations from migrant revenue to core mobile health revenue.
- Higher SG&A expenses in Q4 2024 to support growth and buildout of payer and provider vertical, including investments in people, tech stack, and quality initiatives.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+1.9%
Avg return
Earnings day
+2.0%
Avg return
5 days after
-1.6%
Avg return
30 days after
57%
12 / 21 earnings
Positive
+32.3%
Q2 2021
Best reaction
-40.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.3% | +0.2% | -2.6% | |
| Q4 2025 | +17.7% | +4.0% | -9.7% | |
| Q3 2025 | +0.0% | -3.6% | -15.3% | |
| Q1 2025 | -40.4% | -39.9% | -34.3% | |
| Q4 2024 | -21.2% | -22.4% | -32.7% | |
| Q3 2024 | +9.6% | +14.0% | +11.8% | |
| Q2 2024 | +18.2% | +7.8% | +18.2% | |
| Q1 2024 | -13.5% | -11.2% | -12.6% | |
| Q4 2023 | +4.1% | +0.3% | +3.3% | |
| Q3 2023 | +1.2% | -5.3% | -9.3% | |
| Q2 2023 | +13.9% | +12.1% | -15.6% | |
| Q1 2023 | +5.2% | +2.4% | +11.3% | |
| Q4 2022 | -1.5% | -4.9% | -4.7% | |
| Q3 2022 | -7.7% | -5.1% | -19.8% | |
| Q2 2022 | +4.1% | +16.9% | +11.5% | |
| Q1 2022 | -0.8% | -7.3% | +16.7% | |
| Q2 2021 | +32.3% | +48.9% | +36.2% | |
| Q4 2021 | +13.2% | +39.2% | +29.7% | |
| Q3 2021 | +4.0% | -2.2% | -15.9% | |
| Q1 2021 | -0.4% | -0.4% | -0.1% | |
| Q4 2020 | -0.8% | -0.5% | +0.3% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro